Market Cap 16.84M
Revenue (ttm) 0.00
Net Income (ttm) -44.58M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 3,765,327
Avg Vol 14,877,256
Day's Range N/A - N/A
Shares Out 46.08M
Stochastic %K 31%
Beta 0.52
Analysts Sell
Price Target $4.00

Company Profile

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort,...

Industry: Biotechnology
Sector: Healthcare
Phone: 608 441 8120
Address:
100 Campus Drive, Florham Park, United States
Jamesnewbie
Jamesnewbie Jul. 28 at 6:26 AM
$CLRB 🚀 Cellectar Biosciences – The Next Big Buyout Play! 🚀 Remember back in 2023 when CLRB raised a whopping $103 MILLION led by the powerhouse Rosalind Advisors and backed by top-tier institutional investors like AIGH Capital and Nantahala Capital? That wasn’t just a fundraiser — it was a strategic move setting CLRB on a fast track toward commercialization and a massive exit! These smart money investors know what they’re doing. They believe in iopofosine I 131’s game-changing potential in oncology. The pipeline is strong, the FDA approval is in sight, and the company is locked and loaded for a buyout deal valued easily at $500 MILLION+. 💥 With such heavyweight partners already on board from day one, the path to a lucrative exit looks clearer than ever. Don’t miss out while the smart money quietly accumulates! This could be the deal of the decade. 📈🔥 #CLRB #BiotechBoom #BuyoutAlert #RosalindAdvisors #BigMoneyMoves
1 · Reply
Slab6
Slab6 Jul. 27 at 3:37 PM
$CLRB PAYtience
0 · Reply
Slab6
Slab6 Jul. 27 at 3:13 PM
$CLRB please don’t forget about the PRIME designation, which the EMA itself granted them. Please load up while they’re giving you the chance.
0 · Reply
Slab6
Slab6 Jul. 27 at 3:09 PM
$CLRB waiting game
0 · Reply
EvenBetter99
EvenBetter99 Jul. 27 at 2:00 PM
$CLRB Optimize iopofosine I 131: – Receive FDA Breakthrough Designation – Receive agreement to proceed with Conditional Approval in Europe; supports potential EU commercialization 4Q26/1Q27 – Development and/or commercialization partnerships – Complete Phase 3 and secure approval in US for WM
0 · Reply
MSG8898
MSG8898 Jul. 26 at 3:45 PM
$CLRB it seems like noone in the board did a DD. I reviewed the PRs and the entire process, and here it is: what the co. is waiting for is EMA's invitation (is it basically a non binding preliminary opinion) to file for a MAA with the P2 data submitted, for WM's indication. If the co. receives that, they will go on with the filing, which will then go through the CHMP's opinion and EMA's decision. So basically they are expecting this first step of the process by the end of July, as far as they stated in recent PRs. And yes, it would definitely be a strong catalysts.
2 · Reply
ObsOlet
ObsOlet Jul. 25 at 12:21 PM
$CLRB 🔍 Two possible outcomes during CHMP week: Scenario What happens ✅ iopofosine is listed on the official CHMP agenda CHMP discusses and may issue a recommendation this week on whether Cellectar can proceed with a CMA filing. ❌ Not on the agenda Decision likely occurs in a follow-up process — via internal communication, or through written CHMP procedures later in July or early August. This is common in PRIME reviews.
1 · Reply
Jwvelex
Jwvelex Jul. 25 at 11:58 AM
$CLRB I dont see any mention of CLRB’s I 131 in the recent EMA updates.
1 · Reply
Jamesnewbie
Jamesnewbie Jul. 25 at 3:58 AM
$CLRB Backed by two top-tier Wall Street advisors – Oppenheimer (est. 1881) & Roth Capital – both known for structuring biotech M&A & licensing deals. Lead drug iopofosine I-131 just got FDA Breakthrough Therapy Designation + EMA decision expected late July. Phase 2b showed 83% ORR in an ultra-rare cancer with no FDA-approved drugs. 👀 This is no longer a preclinical story — they’re prepping for commercialization or buyout. Serious suitors may already be circling. With ultra-low float & major catalysts ahead, don’t be late when institutions step in.
1 · Reply
higgggghhhher
higgggghhhher Jul. 25 at 1:16 AM
$CLRB new data was submitted to ema all data across the board should be better. There’s really no reason for conditional approval. None. Literally zero treatments available and our response rate is great and it’s not toxic as well. It literally give patients an option to live.
0 · Reply
Latest News on CLRB
Cellectar Announces Plan to Explore Strategic Alternatives

Apr 30, 2025, 8:05 AM EDT - 3 months ago

Cellectar Announces Plan to Explore Strategic Alternatives


Cellectar Biosciences Inc. (CLRB) Q4 2024 Earnings Call Transcript

Mar 13, 2025, 12:41 PM EDT - 4 months ago

Cellectar Biosciences Inc. (CLRB) Q4 2024 Earnings Call Transcript


Jamesnewbie
Jamesnewbie Jul. 28 at 6:26 AM
$CLRB 🚀 Cellectar Biosciences – The Next Big Buyout Play! 🚀 Remember back in 2023 when CLRB raised a whopping $103 MILLION led by the powerhouse Rosalind Advisors and backed by top-tier institutional investors like AIGH Capital and Nantahala Capital? That wasn’t just a fundraiser — it was a strategic move setting CLRB on a fast track toward commercialization and a massive exit! These smart money investors know what they’re doing. They believe in iopofosine I 131’s game-changing potential in oncology. The pipeline is strong, the FDA approval is in sight, and the company is locked and loaded for a buyout deal valued easily at $500 MILLION+. 💥 With such heavyweight partners already on board from day one, the path to a lucrative exit looks clearer than ever. Don’t miss out while the smart money quietly accumulates! This could be the deal of the decade. 📈🔥 #CLRB #BiotechBoom #BuyoutAlert #RosalindAdvisors #BigMoneyMoves
1 · Reply
Slab6
Slab6 Jul. 27 at 3:37 PM
$CLRB PAYtience
0 · Reply
Slab6
Slab6 Jul. 27 at 3:13 PM
$CLRB please don’t forget about the PRIME designation, which the EMA itself granted them. Please load up while they’re giving you the chance.
0 · Reply
Slab6
Slab6 Jul. 27 at 3:09 PM
$CLRB waiting game
0 · Reply
EvenBetter99
EvenBetter99 Jul. 27 at 2:00 PM
$CLRB Optimize iopofosine I 131: – Receive FDA Breakthrough Designation – Receive agreement to proceed with Conditional Approval in Europe; supports potential EU commercialization 4Q26/1Q27 – Development and/or commercialization partnerships – Complete Phase 3 and secure approval in US for WM
0 · Reply
MSG8898
MSG8898 Jul. 26 at 3:45 PM
$CLRB it seems like noone in the board did a DD. I reviewed the PRs and the entire process, and here it is: what the co. is waiting for is EMA's invitation (is it basically a non binding preliminary opinion) to file for a MAA with the P2 data submitted, for WM's indication. If the co. receives that, they will go on with the filing, which will then go through the CHMP's opinion and EMA's decision. So basically they are expecting this first step of the process by the end of July, as far as they stated in recent PRs. And yes, it would definitely be a strong catalysts.
2 · Reply
ObsOlet
ObsOlet Jul. 25 at 12:21 PM
$CLRB 🔍 Two possible outcomes during CHMP week: Scenario What happens ✅ iopofosine is listed on the official CHMP agenda CHMP discusses and may issue a recommendation this week on whether Cellectar can proceed with a CMA filing. ❌ Not on the agenda Decision likely occurs in a follow-up process — via internal communication, or through written CHMP procedures later in July or early August. This is common in PRIME reviews.
1 · Reply
Jwvelex
Jwvelex Jul. 25 at 11:58 AM
$CLRB I dont see any mention of CLRB’s I 131 in the recent EMA updates.
1 · Reply
Jamesnewbie
Jamesnewbie Jul. 25 at 3:58 AM
$CLRB Backed by two top-tier Wall Street advisors – Oppenheimer (est. 1881) & Roth Capital – both known for structuring biotech M&A & licensing deals. Lead drug iopofosine I-131 just got FDA Breakthrough Therapy Designation + EMA decision expected late July. Phase 2b showed 83% ORR in an ultra-rare cancer with no FDA-approved drugs. 👀 This is no longer a preclinical story — they’re prepping for commercialization or buyout. Serious suitors may already be circling. With ultra-low float & major catalysts ahead, don’t be late when institutions step in.
1 · Reply
higgggghhhher
higgggghhhher Jul. 25 at 1:16 AM
$CLRB new data was submitted to ema all data across the board should be better. There’s really no reason for conditional approval. None. Literally zero treatments available and our response rate is great and it’s not toxic as well. It literally give patients an option to live.
0 · Reply
Jamesnewbie
Jamesnewbie Jul. 24 at 9:58 PM
$CLRB The EMA will release the Meeting Highlights tomorrow, July 25 — a summary of internal discussions on dossiers under review. • If the document includes keywords such as “iopofosine”, “conditional marketing authorisation”, or “PRIME”, this will be a strong signal that the EMA is allowing CLRB to submit its MAA/CMA. • If that happens, the stock could hit $50, possibly even $200 if multiple big pharma companies join the deal.
2 · Reply
MSG8898
MSG8898 Jul. 24 at 8:59 PM
$CLRB ioposofine not on CHMP's July agenda. I guess mid August.
3 · Reply
TwongStocks
TwongStocks Jul. 24 at 8:03 PM
One month post-RS recap. $JDZG 1:8 RS on Jun 24, closed $2.709 Day of the RS, hit a low of $$2.071. However, has traded above that since. From Jun 25-Jul 14, daily volume was under 100k, with a low of 7700 vol on Jul 14. On Jul 16, over 1m vol and closed at $3.55. Next day, hit a high of $3.805. Today closed $2.54, down 6.24% from RS close. $CLRB 1:30 RS on Jun 24, closed $9.70 Reached a high of $10.19 the day after the RS. However, has traded below that since. Announced an offering on Jul 1. Closed in $4S and $5S since. Today closed $5.35, down 44.85% from RS close
0 · Reply
DaniMR83
DaniMR83 Jul. 24 at 5:15 PM
$CLRB No news about EMA?
2 · Reply
NjordTrade
NjordTrade Jul. 24 at 4:58 PM
$CLRB 👀
0 · Reply
S2K_TradeZ
S2K_TradeZ Jul. 24 at 2:07 PM
$CLRB Very tight chart, low floats, and real catalysts rolling in. Breakout at 6.5 can trigger a quick spike. Watching this tape tells the story. 🚨
0 · Reply
Mister___B
Mister___B Jul. 24 at 2:00 PM
In da $CLRB we all fam
0 · Reply
szcyxzh
szcyxzh Jul. 24 at 9:27 AM
$CLRB EPO does not equal to EMA decision. Be very careful about any single word from this management.
0 · Reply
Pedelco
Pedelco Jul. 24 at 4:08 AM
$CLRB 76$ lets get the 52-week high
0 · Reply
VDiesel
VDiesel Jul. 23 at 11:57 PM
$CLRB New Patent Granted for EU. EMA approval this week as well could soar this above $40!
0 · Reply
S2K_TradeZ
S2K_TradeZ Jul. 23 at 10:17 PM
$CLRB 6 break on watch tomorrow. Cheers, Bulls!
0 · Reply
MSG8898
MSG8898 Jul. 23 at 8:42 PM
$CLRB Someone wanted in badly at close
0 · Reply